

**Table S3**

Sensitivity analyses for primary switch (n=65):

<b>Switch distance</b>		
<b>Distance between last A<sup>a</sup>/R<sup>b</sup> and first B<sup>c</sup> [in days]</b>	80.2± 4.1	
<b>Drug exposure</b>		
<b>Therapy time [in years]</b>	<b>Before switch</b>	<b>After switch</b>
	2.9± 0.3	0.84± 0.1
<b>Number of IVT-injections</b>	16.3± 1.5	7.78± 0.5
<b>Interval between last two recorded IVT-injections [in days]</b>	39± 3.1	39.8± 2.1
<b>Assigned finding distances</b>		
<b>IVT-injection to BCVA distance [in days]</b>	<b>Before switch</b>	<b>After switch</b>
	37.2± 3.3	37.2± 2.2
<b>IVT-injection to OCT distance [in days]</b>	36.8± 2.1	36.2± 1.9

<sup>a</sup>A, aflibercept; <sup>b</sup>R, ranibizumab; <sup>c</sup>B, bevacizumab

